Originally posted by pfeifer1982
Here is our asthma update, was published in the leading peer reviewed publication FASEB Journal:
- I have highlighted a few parts in
bold -
iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid
Simon G. Royce,
WeiYi Mao
,
Rebecca Lim
,
Kilian Kelly
, and
Chrishan S. Samuel
Published Online: 15 Feb 2019 https://doi.org/10.1096/fj.201802307R
(Early Online Access)
Abstract
The airway remodeling (AWR) associated with chronic allergic airways disease (AAD)/asthma contributes to irreversible airway obstruction. This study compared and combined the antiremodeling and other effects of induced pluripotent stem cell and mesenchymoangioblast–derived mesenchymal stem cells (MCA-MSCs) with the corticosteroid dexamethasone (Dex) in experimental chronic AAD/asthma. Female BALB/c mice subjected to 11 wk of ovalbumin (Ova)-induced chronic AAD were intranasally administered MCA-MSCs (1 × 106 cells/mouse; once weekly on wk 10 and 11), Dex (0.5 mg/ml; once daily for 2 wk), or both combined. MCA-MSC detection and changes in airway inflammation (AI),
AWR, and airway hyperresponsiveness (AHR) were measured at the end of wk 11. Mice with chronic AAD had significant AI, goblet cell metaplasia, epithelial damage/thickening, aberrant TGF-β1 levels, subepithelial myofibroblast accumulation, airway/lung fibrosis, and AHR (all P < 0.001 vs. healthy controls). MCA-MSCs were detected in the lungs up to 5–7 d postadministration and
demonstrated modest anti-inflammatory but
striking antifibrotic effects against Ova-induced AAD, effectively decreasing AHR by 70–75% (all P < 0.05 vs. Ova alone). In comparison, Dex predominantly demonstrated anti-inflammatory effects, decreasing AHR by ∼30%. Combining MCA-MSCs with Dex provided equivalent protection to that offered by either therapy alone.
MCA-MSCs reduce chronic AAD-induced AWR and AHR to a greater extent than Dex and may act as a suitable adjunct therapy to corticosteroid treatment of asthma.
https://www.fasebj.org/doi/abs/10.1096/fj.201802307R?journalCode=fasebjAnnouncement on Monday?
HotCopper Announcement 22 February 2019
Exciting Data from Cynata MSCs in Third Preclinical Asthma Study
- Cymerus MSCs combined with corticosteroid significantly reduced goblet cell metaplasia
- Cymerus MSCs alone and in combination with DEX significantly reduced ECM deposition to a significantly greater extent than DEX
- Cymerus MSCs alone or in combination with DEX were able to normalise the OVA-induced increase in both epithelial damage and TGF-1 expression and to a greater extent that DEX alone
- Cymerus MSCs alone and in combination with DEX were able to reduce the OVA-induced increased in subepithelial myofibroblast density by ~62-66%, and to a greater extent that DEX alone
- MCA-MSC-and MCA-MSC+DEX-treatment of OVA injured mice significantly promoted MMP-9 expression
- the striking anti-remodelling and anti-fibrotic effects demonstrated by Cymerus MSCs alone or in combination with DEX resulted in their ability to reduce the OVA-induced increase in AHR by ~70-75% in the ongoing progression of disease pathology; which was also to a significantly greater extent than DEX alone
Sydney, Australia; 22 February 2019: HotCopper poster and Twitter abuser pfeifer1982, is pleased to announce further outstanding data supporting the efficacy of Cynata's proprietary Cymerus Mesenchymal Stem Cells (MSCs) in a third preclinical asthma study.
These exciting results lead on from previously-reported studies (announced 2 March 2017 and 23 August 2017).
"To say that these results are encouraging is an understatement. These further studies, which I believe may indicate potential for Cynata's MSCs in both allergic lung diseases and lungfibrotic disorders, such as idiopathic pulmonary fibrosis (IPF), have shown yet again the enormous potential of Cymerus MSCs", said pfeifer1982. "I am looking forward to a clinical application of these cells in the not to distant future", he added.
Contacts: Please don't, but if you have to, reply to this post.
About Cynata Therapeutics (ASX: CYP)
Find everything you need to know on
https://www.cynata.com/
About the Preclinical Study
https://www.fasebj.org/doi/abs/10.1096/fj.201802307R?journalCode=fasebj
About the authors of this Faseb Journal Article
Simon G. Royce
,
WeiYi Mao
,
Rebecca Lim
,
Kilian Kelly
, and
Chrishan S. Samuel
(20min delay)